Pay in 4 interest-free payments of $5.35 Learn more
Ships within 48 hours · Estimated delivery Aug 14 - Aug 19
CagriSema Phase 2 Proof-of-Concept (NCT04982575) Study Title: "Efficacy and Safety of Cagrilintide 2.4 mg in Combination With Semaglutide 2.4 mg for Weight Management" Status: Completed Phase: Phase 2 Enrollment: 92 participants Study Period: 2021-2022 Design: Randomized, double-blind, active-controlled Duration: 32 weeks Arms: CagriSema vs
20 units = 0.20 mL
Identification of blood MicroRNA alterations in patients with severe active alopecia areata
Abdel-Naim, Faculty of Pharmacy, Ain Shams University, Egypt Received: January 21, 2012
US$ 20.86
US$ 23.36
US$ 23.03
US$ 27.92
US$ 21.97
US$ 20.59
US$ 24.37
US$ 24.53
US$ 21.91
